CellTrend receives new patent

In 2018, James P. Allison and Tasuku Honjo received the Nobel Prize in Medicine for the discovery of a tumor therapy through negative immune regulation. Here, the binding between PD1 (Programmed cell death protein 1) and PD-L1 (Programmed cell death protein 1 ligand) is inhibited. CellTrend has discovered autoantibodies against PD1 and PD-L1 in tumor…

Details

New study about severity of Long-COVID symptoms and their correlation with the increased level of autoantibodies was published

A new study about severity of neurological Long-COVID symptoms and their correlation with the increased level of autoantibodies was published. In Table 1 you can have a look at the 200 individuals which were recruited and put into 3 groups. One group with 72 patients were diagnosed with Long-COVID, second group with 58 patients had…

Details

Christmas holidays

We wish you a Merry Christmas and a Happy New Year 2024!   Please note that our laboratory will be closed from 23.12.23 until 01.01.2024 due to the Christmas holidays. During this period, patient samples will not be accepted! The last diagnostics of the patient samples will take place on 14.12.2023!   From 02.01.2024 we…

Details

CellTrend cooperates with the DHZ in Cologne

CellTrend cooperates with Dr. Atheer Al-Nakkash, specialist for transfusion medicine at the “Deutsches Hämapherese Zentrum” in Cologne! The range of services offered there includes a variety of treatments. Among other things, Hemapheresis (removal of blood components outside the body) is used for chronic forms of autoimmune diseases such as Long Covid/PostCovid or ME/CFS. For more…

Details